Cargando…

Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco

BACKGROUND: We provide national estimates of the real-world Vaccine effectiveness (VE) based on nationally available surveillance data. The study aimed to estimate the effectiveness of the inactivated Covid-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm vaccine currently deployed in Morocco against SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Belayachi, Jihane, Obtel, Majdouline, Mhayi, Abdelkader, Razine, Rachid, Abouqal, Redouane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728886/
https://www.ncbi.nlm.nih.gov/pubmed/36477077
http://dx.doi.org/10.1371/journal.pone.0278546
_version_ 1784845364384235520
author Belayachi, Jihane
Obtel, Majdouline
Mhayi, Abdelkader
Razine, Rachid
Abouqal, Redouane
author_facet Belayachi, Jihane
Obtel, Majdouline
Mhayi, Abdelkader
Razine, Rachid
Abouqal, Redouane
author_sort Belayachi, Jihane
collection PubMed
description BACKGROUND: We provide national estimates of the real-world Vaccine effectiveness (VE) based on nationally available surveillance data. The study aimed to estimate the effectiveness of the inactivated Covid-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm vaccine currently deployed in Morocco against SARS- CoV-2 severe disease/ hospitalization” within 9 months after vaccination. METHODS: We conducted a test-negative, case-control study among a population aged 18 years or older who were tested by rt-PCR for SARS-CoV-2 infection from February to October 2021 in Morocco. From the national laboratory COVID-19 database; we identified cases who were rt-PCR positive amongst severe and critical COVID-19 cases and controls who had a negative rt-PCR test for SARS-CoV-2. From the national vaccination register (NVR); individuals vaccinated with COVID-19 Vaccine (Vero Cell) and those unvaccinated were identified and included in the study. The linkage between databases was conducted for the study of Vaccination status based on the timing of the vaccine receipt relative to the SARS-CoV-2 rt-PCR test date. For each person, who tested positive for SARS-CoV-2, we identified a propensity score-matched control participant who was tested negative. We estimated vaccine effectiveness against SARS- CoV-2 severe disease/ hospitalization using conditional logistic regression. RESULTS: Among 12884 persons who tested positive and 12885 propensity score-matched control participants, the median age was 62 years, 47.2% of whom were female. As a function of time after vaccination of second dose vaccination, vaccine effectiveness during the first month was 88% (95% CI, 84–91), 87% (95% CI: 83–90) during the second and third month, 75% (95% CI: 67–80) during the fourth month, 61% (95% CI: 54–67) during the fifth month, and 64% (95% CI: 59–69) beyond the sixth month. VE remained high and stable during the first three months in the two-age subgroup. In the fourth month, the VE in the older population aged 60 years and above (64%) was reduced by 20 points compared to VE in the younger population (84%). CONCLUSION: A Sinopharm vaccine is highly protective against serious SARS-CoV-2 infection under real-world conditions. Protection remained high and stable during the first three months following the second dose and decreases slightly beyond the fourth month especially beyond 60 years.
format Online
Article
Text
id pubmed-9728886
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-97288862022-12-08 Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco Belayachi, Jihane Obtel, Majdouline Mhayi, Abdelkader Razine, Rachid Abouqal, Redouane PLoS One Research Article BACKGROUND: We provide national estimates of the real-world Vaccine effectiveness (VE) based on nationally available surveillance data. The study aimed to estimate the effectiveness of the inactivated Covid-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm vaccine currently deployed in Morocco against SARS- CoV-2 severe disease/ hospitalization” within 9 months after vaccination. METHODS: We conducted a test-negative, case-control study among a population aged 18 years or older who were tested by rt-PCR for SARS-CoV-2 infection from February to October 2021 in Morocco. From the national laboratory COVID-19 database; we identified cases who were rt-PCR positive amongst severe and critical COVID-19 cases and controls who had a negative rt-PCR test for SARS-CoV-2. From the national vaccination register (NVR); individuals vaccinated with COVID-19 Vaccine (Vero Cell) and those unvaccinated were identified and included in the study. The linkage between databases was conducted for the study of Vaccination status based on the timing of the vaccine receipt relative to the SARS-CoV-2 rt-PCR test date. For each person, who tested positive for SARS-CoV-2, we identified a propensity score-matched control participant who was tested negative. We estimated vaccine effectiveness against SARS- CoV-2 severe disease/ hospitalization using conditional logistic regression. RESULTS: Among 12884 persons who tested positive and 12885 propensity score-matched control participants, the median age was 62 years, 47.2% of whom were female. As a function of time after vaccination of second dose vaccination, vaccine effectiveness during the first month was 88% (95% CI, 84–91), 87% (95% CI: 83–90) during the second and third month, 75% (95% CI: 67–80) during the fourth month, 61% (95% CI: 54–67) during the fifth month, and 64% (95% CI: 59–69) beyond the sixth month. VE remained high and stable during the first three months in the two-age subgroup. In the fourth month, the VE in the older population aged 60 years and above (64%) was reduced by 20 points compared to VE in the younger population (84%). CONCLUSION: A Sinopharm vaccine is highly protective against serious SARS-CoV-2 infection under real-world conditions. Protection remained high and stable during the first three months following the second dose and decreases slightly beyond the fourth month especially beyond 60 years. Public Library of Science 2022-12-07 /pmc/articles/PMC9728886/ /pubmed/36477077 http://dx.doi.org/10.1371/journal.pone.0278546 Text en © 2022 Belayachi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Belayachi, Jihane
Obtel, Majdouline
Mhayi, Abdelkader
Razine, Rachid
Abouqal, Redouane
Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco
title Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco
title_full Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco
title_fullStr Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco
title_full_unstemmed Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco
title_short Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco
title_sort long term effectiveness of inactivated vaccine bbibp-corv (vero cells) against covid-19 associated severe and critical hospitalization in morocco
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728886/
https://www.ncbi.nlm.nih.gov/pubmed/36477077
http://dx.doi.org/10.1371/journal.pone.0278546
work_keys_str_mv AT belayachijihane longtermeffectivenessofinactivatedvaccinebbibpcorvverocellsagainstcovid19associatedsevereandcriticalhospitalizationinmorocco
AT obtelmajdouline longtermeffectivenessofinactivatedvaccinebbibpcorvverocellsagainstcovid19associatedsevereandcriticalhospitalizationinmorocco
AT mhayiabdelkader longtermeffectivenessofinactivatedvaccinebbibpcorvverocellsagainstcovid19associatedsevereandcriticalhospitalizationinmorocco
AT razinerachid longtermeffectivenessofinactivatedvaccinebbibpcorvverocellsagainstcovid19associatedsevereandcriticalhospitalizationinmorocco
AT abouqalredouane longtermeffectivenessofinactivatedvaccinebbibpcorvverocellsagainstcovid19associatedsevereandcriticalhospitalizationinmorocco